Hls Therapeutics — FY2021 Earnings Presentation

5 slides from Hls Therapeutics's earnings presentation, Mar 17, 2022

Slide 1: Q4 & F2021 Results Conference Call
Gilbert Godin | CEO Tim Hendrickson | CFO Q4 & F2021 Results Conference Call March 17, 2022 TSX - HLS
Slide 2: Forward-looking statements
Forward-looking statements Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not alwa
Slide 3: F2021: laying groundwork for Vascepa expansion
F2021: laying groundwork for Vascepa expansion 20 international medical societies >90% recommend the use of Vascepa private payer coverage Patient count since 6097 Vascepa launch 5053 Salesforce Expansion Physician count since 4091 >3x increase in sales reps and >4x increase in coverage Vascepa laun
Slide 4: Vascepa: prescription momentum growing
Vascepa: prescription momentum growing… Weekly script data since launch …fueled by growth catalysts 800 700 Private market access • >90% eligible for coverage 600 Prescriptions Inclusion in Canadian medical 500 society guidelines • Canadian Cardiovascular Society, 400 Heart & Stroke, Thrombosis Cana
Slide 5: Q4 & F2021 Results Conference Call
Gilbert Godin | CEO Tim Hendrickson | CFO Q4 & F2021 Results Conference Call March 17, 2022 TSX - HLS